Annual review of nutrition

The Challenges and Potential of Combining GLP-1 and GIP Treatments: How They Work and How Well They Help

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

GLP-1-based obesity pharmacotherapies, including semaglutide, have significantly advanced obesity treatment.

  • GLP-1 receptor agonists are effective in obesity management.
  • The dual agonist tirzepatide and antagonist maridebart cafraglutide target both GLP-1 and GIP receptors.
  • Targeting GIP receptors may lead to improved metabolic outcomes.
  • There is currently no evidence for anorectic effects of GIP receptor agonism or antagonism alone in humans.
  • Dual targeting of GIPR and GLP-1R may offer greater efficacy than semaglutide.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Jul '26
A molecule that first activates then blocks two hormone receptors leads to greater weight loss in obese mice
journal article
Nov '24
Why combining GLP-1 with GIP and/or GCG agonists causes more weight loss than GLP-1 alone in obese adults without diabetes
top 5% journal
cited by 29 papers
journal article
Apr '26
Possible benefits of GIP hormone in type 2 diabetes and obesity
journal article
Nov '24
Loss of a specific signaling in inhibitory brain cells increases weight loss caused by GLP-1 receptor drugs
top 5% journal
cited by 19 papers
journal article
Dec '18
Improved GIP-like drugs reduce body weight in mice by activating, not blocking, GIP receptors
top 5% journal
cited by 225 papers
research support, non-u.s. gov't
Feb '23
Fat around the human heart contains receptors for glucose-related hormones that could be targets for multiple treatments
top 5% journal
cited by 99 papers
research support, non-u.s. gov't
Oct '25
New GLP-1 Treatments for Diabetes and Obesity
top 1% journal
cited by 39 papers
journal article
Jul '25
Cost-effectiveness of four diabetes-related hormone treatments for overweight and obese adults in China
top 5% journal
cited by 3 papers
research support, non-u.s. gov't

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #59
GLP-1 drugs linked to fewer psychiatric hospitalizations in schizophrenia patients with diabetes
2 weeks ago7 studies
issue #58
A new triple receptor drug cut body weight by nearly 20% in 24 weeks
3 weeks ago7 studies
issue #57
A triple-receptor obesity drug just posted 25–35% weight loss in a phase 3 trial
4 weeks ago7 studies
issue #56
Semaglutide cut heart attack risk by 20% — but weight loss explains less than half of it
5 weeks ago7 studies
issue #55
The brain circuit that makes GLP-1 drugs work also causes nausea — and they can't be separated
6 weeks ago7 studies
issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
7 weeks ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
8 weeks ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
9 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
10 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
11 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief